Cellular And Gene Therapy Trial Design: Draft Guidance Highlights Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA provides advice on designing early-phase trials to assess safety, tolerability and feasibility of administering cellular therapy and gene therapy products but stresses the unique risks of these products.
You may also be interested in...
Ocular Gene Therapy Sees The Light
Recent scientific advances and some initial biotech successes have spurred investors to look again at gene therapy, a space once given up for dead. Gene therapies seem particularly apt for ocular diseases, but the pathway to approval remains largely uncharted for young companies such as the four we profile in this issue: Avalanche Biotechnologies, Eyevensys, GenSight Biologics, and Hemera Biosciences.
Financings Of The Fortnight: Bluebird IPO Could Provide Validation For Gene Therapy As A Modality
During a year in which biotech IPOs have taken off, the bluebird bio issue calls for special attention. Plus news on recent financings by Quintiles, Portola, Isis and Lumena.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.